|
|
|
||||
MPhA 2010 Spring ConferenceApril 28, 2010
Four Points Sheraton1125 Boston Providence Turnpike Norwood, MA 02062 Registration is now closed. Exhibitors and Sponsors [click here] to download a registration form SCHEDULE OF EVENTS
7:30 am - 8:00 am
Registration & Continental Breakfast
7:45 am—8:00 am
Welcoming Remarks
Anne McDonnell, Pharm.D., President
Massachusetts Pharmacists Association
8:00 am - 9:00 am
Anticoagulation Update
0106-9999-10-001-L01-P (0.1 CEUs)
Karen Fiumara, PharmD., Patient Safety Manager, Brigham and Women’s Hospital, Boston, MA
After completion of this activity, participants should be able to:
1. State the epidemiology, burden, and new safety goals associated with Venous Thromboembolism (VTE);
2.Review the evidence on new and current options for VTE treatment and prophylaxis;
3. Identify strategies to increase routine use of VTE prophylaxis.
Supported by educational grants from Ortho-McNeil Janssen Scientific Affairs, LLC & Sanofi-Aventis 9:05 am - 10:05 am
Managing Asthma in an Outpatient Setting: Updates All Pharmacists Should Know!
0106-9999-10-002-L01-P (0.1 CEUs)
Timothy R. Hudd, BS, Pharm.D., R.Ph., AE-C, Assistant Professor of Pharmacy Practice,
Massachusetts College of Pharmacy and Health Sciences—Boston Clinical Pharmacist - Greater Lawrence Family Health Center After completion of this activity, participants should be able to:
1. Identify asthma triggers and methods to educate patients on how to avoid them;
2. Advise pharmacists and other health providers on appropriate treatment options, based on a patient’s symptoms and various objective measures;
3. Provide strategies to monitor the efficacy of treatment regimens, as well as, ways to avoid adverse effects;
4. Address recent evidence and questions raised by the media surrounding products such as long-acting bronchodilators and leukotriene antagonists.
10:10 am–11:10 am
Opioids for Chronic Non-Cancer Pain: Risk Management Strategies and the Role of the Pharmacist
0106-9999-10-003-L01-P (0.1 CEUs)
Michelle Matthews, Pharm.D., Clinical Pharmacy Specialist, Pain Management Center,
Brigham and Women's Hospital, Boston, MA After completion of this activity, participants should be able to:
1. Define the following terms as they relate to opioid analgesic use: tolerance, physical dependence, addiction, and pseudoaddiction;
2. Analyze the role of opioid analgesics in the management of chronic noncancer pain including appropriate assessment and monitoring;
3. Identify risk management strategies that can be incorporated into practice to prevent opioid misuse and abuse;
4. Describe the role of the pharmacist in the assessment and management of patients with chronic noncancer pain.
Supported by educational grants from Purdue Pharma, L.P. & Ortho-McNeil Janssen Scientific Affairs, LLC 11:15 am - 12:15 pm
New Oral Chemotherapy: Efficacy and Toxicity.
0106-9999-10-004-L01-P (0.1 CEUs)
J. Andrew Skirvin, Pharm.D. BCOP, Hematology/Oncology, Clinical Pharmacist,
Dana Farber Cancer Institute, Boston, MA & Associate Clinical Professor, Northeastern University School of Pharmacy After completion of this activity, participants should be able to:
1. Describe the mechanism of action and indication of new oral chemotherapy agents;
2. Identify common adverse effects and drug-drug interactions with new oral chemotherapy agents;
3. Summarize dosing considerations with new oral chemotherapy agents;
4. Discuss the safe use and dispensing issues related to oral chemotherapy.
12:15 pm - 1:45 pm
Lunch / Exhibition Show
1:45 pm - 2:45 pm
Post Exposure Prophylaxis: What to Do Before it's Too Late
0106-9999-10-005-L01-P (0.1 CEUs)
Jason Lancaster, Pharm.D., BCPS, Clinical Pharmacy Specialist, Lahey Clinic, Burlington, MA,
& Assistant Clinical Professor, Northeastern University School of Pharmacy After completion of this activity, participants should be able to:
1. Differentiate events and exposures that require post-exposure prophylaxis from those that do not;
2. Outline the use of vaccines in adults to eradicate certain diseases;
3. Evaluate the need for the administration of newer vaccines;
4. Given a patient case, determine appropriate vaccine and/or hyperimmune therapy.
Supported by an educational grant from Talecris Biotherapeutics
2:50 pm - 4:50pm
Legislative and Regulatory Update
0106-9999-10-006-L03-P (0.2 CEUS-Law)
Todd Brown, MHP, R.Ph., Vice Chair, Dept. of Pharmacy Practice, Northeastern University School of Pharmacy &
Anita Young, M.Ed., R.Ph., Director of Continuing Education, Northeastern University School of Pharmacy After completion of this activity, participants should be able to:
1. Relate specific regulations under 247 CMR to the practice of pharmacy such as new requirements for CPE, licensure and the new online registration system;
2. Explain the importance of Medication Reconciliation;
3. Describe the requirements of the Pharmaceutical and Medical Device Manufacturer Code of Conduct;
4. Relate the importance of collaborative drug therapy legislation and the potential impact on pharmacy practice;
5. Explain the “Coupon” and “Pharmacy Audit” legislation that are currently being considered by the Massachusetts Legislature;
6. Critique legislation and controversial issues on generic substitution.
Platinum Silver |
|
